Adverse Drug Experiences (All Spontaneous Safety Reports)
| AE | Listed* | Unlisted | Total |
| No. of serious events | 0 | 2 | 2 |
| Serious events | |||
| Blood sodium decreased | x | 1 | |
| Epilepsy | x | 1 | |
| No. of nonserious events | 18 | 14 | 32 |
| Nonserious events | |||
| Injection site pain† | x | 8 | |
| Altered biodistribution | x | 6 | |
| Hypersensitivity‡ | x | 4 | |
| Headache | x | 3 | |
| Nausea‡ | x | 2 | |
| Syncope | x | 2 | |
| Anxiety | x | 1 | |
| Cold sweat | x | 1 | |
| Dysgeusia‡ | x | 1 | |
| Epistaxis | x | 1 | |
| Facial pain | x | 1 | |
| Influenzalike illness | x | 1 | |
| Sense of oppression | x | 1 |
↵* Included in current reference safety information (listed)—that is, European Summary of Product Characteristics (March 2013) or U.S. prescribing information (April 2011).
↵† Added in 2002.
↵‡ Added in 2011.
Approximately half a million doses of DaTscan dispensed in 13-y period. x indicates whether event is currently mentioned in reference safety information (listed) or not (unlisted).